CVS Health (CVS) Receives a Buy from Jefferies

Jefferies analyst Brian Tanquilut maintained a Buy rating on CVS Health (CVSResearch Report) today and set a price target of $130.00. The company’s shares closed last Thursday at $101.87.

According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 6.1% and a 55.6% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Privia Health Group, and Quest Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVS Health with a $119.10 average price target, representing a 16.6% upside. In a report issued on August 3, J.P. Morgan also maintained a Buy rating on the stock with a $130.00 price target.

See the top stocks recommended by analysts >>

CVS Health’s market cap is currently $133.6B and has a P/E ratio of 16.54.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.

Read More on CVS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More